CN117561057A - 用raf抑制剂治疗癌症 - Google Patents

用raf抑制剂治疗癌症 Download PDF

Info

Publication number
CN117561057A
CN117561057A CN202280045318.4A CN202280045318A CN117561057A CN 117561057 A CN117561057 A CN 117561057A CN 202280045318 A CN202280045318 A CN 202280045318A CN 117561057 A CN117561057 A CN 117561057A
Authority
CN
China
Prior art keywords
cancer
braf
inhibitor
compound
embodiment provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280045318.4A
Other languages
English (en)
Chinese (zh)
Inventor
亚历山德拉·弗拉诺维奇
埃里克·马丁
尼科尔·L·G·米勒
埃里克·墨菲
理查德·托马斯·威廉姆斯
小林健
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Jinnaite Biopharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinnaite Biopharmaceutical Co filed Critical Jinnaite Biopharmaceutical Co
Publication of CN117561057A publication Critical patent/CN117561057A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280045318.4A 2021-04-23 2022-04-22 用raf抑制剂治疗癌症 Pending CN117561057A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163178922P 2021-04-23 2021-04-23
US63/178,922 2021-04-23
PCT/US2022/025875 WO2022226261A1 (en) 2021-04-23 2022-04-22 Treatment of cancer with a raf inhibitor

Publications (1)

Publication Number Publication Date
CN117561057A true CN117561057A (zh) 2024-02-13

Family

ID=83722622

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280045318.4A Pending CN117561057A (zh) 2021-04-23 2022-04-22 用raf抑制剂治疗癌症

Country Status (12)

Country Link
US (2) US11918587B2 (https=)
EP (1) EP4326256A4 (https=)
JP (1) JP2024516972A (https=)
KR (1) KR20240000534A (https=)
CN (1) CN117561057A (https=)
AU (1) AU2022261117A1 (https=)
BR (1) BR112023021913A2 (https=)
CA (1) CA3216104A1 (https=)
IL (1) IL307908A (https=)
MX (1) MX2023012515A (https=)
TW (1) TW202308645A (https=)
WO (1) WO2022226261A1 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022007612A2 (pt) 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
CN117561057A (zh) 2021-04-23 2024-02-13 金耐特生物制药公司 用raf抑制剂治疗癌症
AU2024265078A1 (en) 2023-05-04 2025-12-11 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
IL326136A (en) 2023-08-07 2026-03-01 Revolution Medicines Inc RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein
AU2024322235A1 (en) * 2023-08-09 2026-02-26 Pierre Fabre Medicament Treatment of cancer with a raf inhibitor
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025145207A1 (en) * 2023-12-29 2025-07-03 Bristol-Myers Squibb Company Combination therapy of kras inhibitor and treg-depleting agent
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6187799B1 (en) 1997-05-23 2001-02-13 Onyx Pharmaceuticals Inhibition of raf kinase activity using aryl ureas
US20070244120A1 (en) 2000-08-18 2007-10-18 Jacques Dumas Inhibition of raf kinase using substituted heterocyclic ureas
GB9823873D0 (en) 1998-10-30 1998-12-30 Pharmacia & Upjohn Spa 2-ureido-thiazole derivatives,process for their preparation,and their use as antitumour agents
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
WO2006071940A2 (en) 2004-12-23 2006-07-06 Deciphera Pharmaceuticals, Llc Enzyme modulators and treatments
US8188113B2 (en) 2006-09-14 2012-05-29 Deciphera Pharmaceuticals, Inc. Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
AR067354A1 (es) 2007-06-29 2009-10-07 Sunesis Pharmaceuticals Inc Compuestos utiles como inhibidores de la raf quinasa
CA2714700C (en) 2008-02-22 2013-07-30 Irm Llc Heterocyclic compounds and compositions as c-kit and pdgfr kinase inhibitors
EP2112150B1 (en) 2008-04-22 2013-10-16 Forma Therapeutics, Inc. Improved raf inhibitors
WO2010078408A1 (en) 2008-12-30 2010-07-08 Biogen Idec Ma Inc. Heteroaryl compounds useful as raf kinase inhibitors
AR090151A1 (es) 2012-03-07 2014-10-22 Lilly Co Eli Compuestos inhibidores de raf
DK3366293T3 (da) 2012-06-07 2020-06-15 Deciphera Pharmaceuticals Llc Dihydronaphthyridiner og relaterede forbindelser, der er nyttige som kinashæmmere til behandling af proliferative sygdomme
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
US10167279B2 (en) 2014-09-12 2019-01-01 Novartis Ag Compounds and compositions as RAF kinase inhibitors
UY36294A (es) 2014-09-12 2016-04-29 Novartis Ag Compuestos y composiciones como inhibidores de quinasa
WO2020168172A1 (en) 2019-02-15 2020-08-20 Zamboni Chem Solutions Inc. Conjugate compounds for the degradation of raf
JP2022525885A (ja) 2019-03-22 2022-05-20 キネート バイオファーマ インク． Ｒａｆキナーゼの阻害剤
US10927111B2 (en) * 2019-05-03 2021-02-23 Kinnate Biopharma Inc. Inhibitors of RAF kinases
TWI891666B (zh) 2019-10-14 2025-08-01 美商英塞特公司 作為ｆｇｆｒ抑制劑之雙環雜環
BR112022007612A2 (pt) 2019-10-24 2022-09-20 Kinnate Biopharma Inc Inibidores de raf quinases
US11407737B2 (en) * 2020-09-18 2022-08-09 Kinnate Biopharma Inc. Inhibitors of RAF kinases
WO2022081469A1 (en) 2020-10-12 2022-04-21 Kinnate Biopharma Inc. Inhibitors of raf kinases
CN117529313A (zh) 2021-04-23 2024-02-06 金耐特生物制药公司 固态形式的(s)-n-(3-(2-(((r)-1-羟基丙-2-基)氨基)-6-吗啉代吡啶-4-基)-4-甲基苯基)-3-(2,2,2-三氟乙基)吡咯烷-1-甲酰胺及其盐
CN117561057A (zh) * 2021-04-23 2024-02-13 金耐特生物制药公司 用raf抑制剂治疗癌症

Also Published As

Publication number Publication date
EP4326256A1 (en) 2024-02-28
US11918587B2 (en) 2024-03-05
BR112023021913A2 (pt) 2024-01-16
MX2023012515A (es) 2023-12-15
WO2022226261A1 (en) 2022-10-27
JP2024516972A (ja) 2024-04-18
EP4326256A4 (en) 2025-03-19
IL307908A (en) 2023-12-01
TW202308645A (zh) 2023-03-01
US12569496B2 (en) 2026-03-10
CA3216104A1 (en) 2022-10-27
US20240325403A1 (en) 2024-10-03
AU2022261117A1 (en) 2023-11-23
US20230255977A1 (en) 2023-08-17
KR20240000534A (ko) 2024-01-02

Similar Documents

Publication Publication Date Title
CN117561057A (zh) 用raf抑制剂治疗癌症
Zhao et al. The clinical development of MEK inhibitors
JP2022520079A (ja) Ｔｎｏ１５５及びｋｒａｓｇ１２ｃ阻害剤を含む医薬組合せ
JP7490635B2 (ja) Ｅｇｆｒ変異がんの処置
US20140024030A1 (en) Preselection of subjects for therapeutic treatment with oxygen sensitive agents based in hypoxic status
JP2022509262A (ja) 乳癌を有する女性におけるアベマシクリブと組み合わせたエラセストラント
TW202329946A (zh) 用於治療癌症之方法及包含cdk2抑制劑之給藥方案
JP2023534991A (ja) 変異型ｉｄｈ１阻害剤、デオキシアデノシン類似体、及び白金剤を用いた併用療法
US20250032458A1 (en) Treatment of cancer with an fgfr kinase inhibitor
WO2015145388A2 (en) Methods of treating colorectal cancers harboring upstream wnt pathway mutations
WO2024220427A1 (en) Treatment of cancer with a mek kinase inhibitor
CN121001744A (zh) 治疗tki耐药性和sdh缺陷型gist的方法
US20230233567A1 (en) Belvarafenib for use in cancer treatment
AU2024322235A1 (en) Treatment of cancer with a raf inhibitor
CN117794523A (zh) 使用parp抑制剂和plk1抑制剂的癌症治疗
US20250275978A1 (en) Use of onvansertib as monotherapy and in combination with cetuximab in treating ras wild-type colorectal cancer
WO2025162446A1 (zh) 一种egfr抑制剂的用途
HK40087830A (zh) 用於癌症治疗的贝伐非尼
JP2026501284A (ja) リプレチニブを用いて消化管間質腫瘍を治療する方法
AU2021432315A1 (en) Treating cancer in patient having co-occurring genetic alteration in fgfr2 and a cancer driver gene
HK40124174A (zh) Blu-945联合奥斯替尼治疗非小细胞肺癌
WO2019223672A1 (zh) 用于治疗非小细胞肺癌的喹啉衍生物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20240911

Address after: Laval, France

Applicant after: PIERRE FABRE MEDICAMENT

Country or region after: France

Address before: California, USA

Applicant before: Jinnaite biopharmaceutical Co.

Country or region before: U.S.A.

TA01 Transfer of patent application right